Experts in myopia management and irregular corneas will present numerous courses that will help advance the way ECPs deliver clinical care.
CooperVision will shine a spotlight on myopia management and specialty lenses at the 2024 Global Specialty Lens Symposium (GSLS) with multiple education sessions and scientific programs to advance the way that eye care practitioners (ECPs) deliver clinical care. The event—which will take place January 17-20 in Las Vegas—will feature several professional educational sessions, as well as a robust scientific program.
“A huge part of our partner-centric leadership is to provide ECPs with relevant education, high-value tools and resources to help them to grow their practices,” said Tony Sommer, General Manager, Myopia Management & Specialty Contact Lenses, CooperVision, Americas. “Our goal is for ECPs to leave GSLS feeling more confident prescribing our innovative portfolio of contact lenses and positively impacting the quality of life of their patients.”
CooperVision will sponsor multiple discussions surrounding myopia management and irregular cornea over three days, including:
Myopia Management Made Easy with MiSight® 1 day
Breakfast Seminar
Thursday, January 18 | 7:30 – 7:55 a.m. PT
Justin Kwan, OD, FAAO, CooperVision
Elevate Your Empirical Hybrid Fitting Game
Lunch & Learn
Thursday, January 18 | 12:55 – 2:00 p.m. PT
Tiffany Andrzejewski, OD, and Rob Ensley, OD
Building Confidence and Improving First Fit Success with Paragon CRT®
Thursday, January 18 | 2:10 – 2:55 p.m. PT
Maria Liu, OD, FAAO, PhD, UC Berkeley School of Optometry, and Leah Johnson, OD, FAAO, FSLS, CooperVision
Tooling Around…The Latest Innovations in Scleral Lens Fitting Tools
Friday, January 19 | 1:30 – 2:15 p.m. PT
Renee Reeder, OD, FAAO, FSLS and Shalu Pal, OD, FAAO, FSLS
5X Revenue Per Patient with Myopia Management
Friday, January 19 | 5:30 – 6:15 p.m. PT
Justin Kwan, OD, FAAO, CooperVision
Reinventing the Specialty Customer Experience
Breakfast Seminar
Saturday, January 20 | 7:30 – 7:55 a.m. PT
Tony Sommer, MBA, CooperVision and Marie-Christine Blanchard, CooperVision
In addition, the company will share several scientific papers and posters at GSLS, reinforcing its commitment to taking an evidence-based approach to care. Among those are a new exploration of trends in U.S. pediatric eye exams and contact lens prescribing, an in-depth analysis of MiSight® 1 day efficacy for children who exhibit slower and faster myopia progression. More details are expected to be released in the coming days.
Now prescribed in more than 30 countries, CooperVision MiSight® 1 day is the first and only soft contact lens approved by the FDA to both correct vision and slow the progression of myopia in children aged 8-12 at the initiation of treatment.†1 Discover more myopia management resources and learnings at CooperVision’s Online Success Center.
* U.S. Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
† Compared to a single vision 1 day lens over a 3-year period.
References
1. Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567.
